Characteristics of a COPD population categorised using the GOLD framework by health status and exacerbations

被引:54
作者
Jones, Paul W. [1 ]
Nadeau, Gilbert [2 ]
Small, Mark [3 ]
Adamek, Lukasz [2 ]
机构
[1] Univ London, London, England
[2] GSK, Resp Ctr Excellence, Uxbridge, Middx, England
[3] Adelphi Grp, Adelphi Real World, Macclesfield, Cheshire, England
关键词
COPD; GOLD; CAT; Exacerbations; OBSTRUCTIVE PULMONARY-DISEASE; PREVENTION; PREVALENCE; PROPIONATE; DIAGNOSIS; PHYSICIAN; IMPACT;
D O I
10.1016/j.rmed.2013.08.015
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
GOLD proposed a COPD assessment framework focussed on symptoms measured by the COPD Assessment Test (TM) (CAT) or the mMRC and on exacerbation risk based on poor lung function (FEV1 <50%) or a history of >= 2 exacerbations in the previous year. This analysis examined the characteristics of COPD patients recruited from routine clinical settings and classified using the GOLD framework. 1041 European COPD patients (38.5% from primary care) from the Adelphi Respiratory Disease Specific Programme with information on CAT, mMRC, spirometry and exacerbation history in the previous year were analysed. Their mean age was 64.9 +/- 9.9 years and mean FEV1 was 62.5 +/- 17.8% predicted; 80% were in GOLD 2 spirometric grade or milder. CAT and nnMRC cut points identified different groups of patients; using CAT, the composition was: Group A 9.3%, Group B 48.5%, Group C 0.7% and Group D 41.5%. 80% were classified as high risk based on exacerbation history and 25% of patients in a low risk category (GOLD A and B) had 1 exacerbation in the previous year. The incidence of diabetes, hypertension and hyperlipidaemia rose with worsening GOLD group (all p < 0.0001); diabetes GOLD A 4%, GOLD B 16%, GOLD D 29%; hypertension GOLD A 38%, GOLD B 55%, GOLD D 65%; hyperlipidaemia GOLD A 13%, GOLD B 30%, GOLD D 37%. In patients seen in routine clinical settings, 25% of GOLD low risk patients had one exacerbation per year and the incidence of cardio-vascular and metabolic diseases increases with worsening GOLD group. (C) 2013 The Authors. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:129 / 135
页数:7
相关论文
共 23 条
[1]
Agusti A, 2013, EUR RESP J
[2]
Characterisation of COPD heterogeneity in the ECLIPSE cohort [J].
Agusti, Alvar ;
Calverley, Peter M. A. ;
Celli, Bartolome ;
Coxson, Harvey O. ;
Edwards, Lisa D. ;
Lomas, David A. ;
MacNee, William ;
Miller, Bruce E. ;
Rennard, Steve ;
Silverman, Edwin K. ;
Tal-Singer, Ruth ;
Wouters, Emiel ;
Yates, Julie C. ;
Vestbo, Jorgen .
RESPIRATORY RESEARCH, 2010, 11
[3]
Real-world physician and patient behaviour across countries: Disease-Specific Programmes - a means to understand [J].
Anderson, P. ;
Benford, M. ;
Harris, N. ;
Karavali, M. ;
Piercy, J. .
CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (11) :3063-3072
[4]
Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease [J].
Bestall, JC ;
Paul, EA ;
Garrod, R ;
Garnham, R ;
Jones, PW ;
Wedzicha, JA .
THORAX, 1999, 54 (07) :581-586
[5]
Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial [J].
Burge, PS ;
Calverley, PMA ;
Jones, PW ;
Spencer, S ;
Anderson, JA ;
Maslen, TK .
BMJ-BRITISH MEDICAL JOURNAL, 2000, 320 (7245) :1297-1303
[6]
Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease [J].
Calverley, PM ;
Boonsawat, W ;
Cseke, Z ;
Zhong, N ;
Peterson, S ;
Olsson, H .
EUROPEAN RESPIRATORY JOURNAL, 2003, 22 (06) :912-919
[7]
Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease - Results from the TORCH study [J].
Celli, Bartolome R. ;
Thomas, Nicola E. ;
Anderson, Julie A. ;
Ferguson, Gary T. ;
Jenkins, Christine R. ;
Jones, Paul W. ;
Vestbo, Jorgen ;
Knobil, Katharine ;
Yates, Julie C. ;
Calverley, Peter M. A. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2008, 178 (04) :332-338
[8]
Impact of COPD exacerbations on patient-centered outcomes [J].
Cote, Claudia G. ;
Dordelly, Luis J. ;
Celli, Bartolome R. .
CHEST, 2007, 131 (03) :696-704
[9]
FLETCHER CM, 1952, P ROY SOC MED, V45, P577
[10]
Han MK, 2012, LANCET RESP MED, DOI DOI 10.1016/52213-2600(12)70044-9.SEPTEMBER